Fludeoxyglucose f 18
Fludeoxyglucose F (fludeoxyglucose f 18) is a small molecule pharmaceutical. Fludeoxyglucose f 18 was first approved as Fludeoxyglucose f18 on 1994-08-19.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| fludeoxyglucose | ANDA | 2024-10-25 |
| fludeoxyglucose f 18 | ANDA | 2024-10-21 |
| fludeoxyglucose f-18 | ANDA | 2024-04-01 |
| fludeoxyglucose f18 | ANDA | 2024-10-11 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
1520 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 39 | 25 | 2 | 3 | 77 | 138 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 16 | 33 | 10 | 2 | 74 | 128 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 18 | 30 | 1 | 2 | 70 | 117 |
| Inflammation | D007249 | MP_0001845 | — | 8 | 4 | 3 | 9 | 31 | 53 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 4 | 9 | — | 1 | 29 | 43 |
| Uterine cervical neoplasms | D002583 | HP_0030159 | — | 8 | 11 | 3 | 1 | 17 | 37 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 5 | 4 | 3 | 2 | 23 | 36 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | 3 | 4 | — | 2 | 21 | 30 |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 3 | 8 | 1 | 1 | 16 | 28 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 9 | 2 | 1 | 2 | 14 | 26 |
Show 66 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 14 | 38 | 18 | — | 67 | 130 |
| Carcinoma | D002277 | — | C80.0 | 24 | 35 | 5 | — | 58 | 115 |
| Non-small-cell lung carcinoma | D002289 | — | — | 14 | 31 | 6 | — | 55 | 101 |
| Head and neck neoplasms | D006258 | — | — | 12 | 8 | 3 | — | 41 | 61 |
| Squamous cell carcinoma | D002294 | — | — | 12 | 12 | 4 | — | 18 | 42 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 10 | 13 | 2 | — | 18 | 40 |
| Hodgkin disease | D006689 | — | C81 | 3 | 16 | 10 | — | 11 | 39 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 5 | 13 | 1 | — | 18 | 36 |
| Esophageal neoplasms | D004938 | — | C15 | 6 | 9 | 1 | — | 22 | 35 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 3 | 4 | 2 | — | 21 | 29 |
Show 41 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 7 | 11 | — | — | 23 | 39 |
| Melanoma | D008545 | — | — | 3 | 7 | — | — | 22 | 32 |
| Recurrence | D012008 | — | — | 8 | 14 | — | — | 13 | 32 |
| Adenocarcinoma | D000230 | — | — | 10 | 15 | — | — | 9 | 32 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 6 | 6 | — | — | 15 | 26 |
| Positron-emission tomography | D049268 | — | — | 2 | 1 | — | — | 24 | 26 |
| Rectal neoplasms | D012004 | — | — | 2 | 6 | — | — | 17 | 24 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 7 | 6 | — | — | 13 | 24 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 6 | 4 | — | — | 12 | 22 |
| Glioma | D005910 | EFO_0000520 | — | 7 | 4 | — | — | 11 | 21 |
Show 157 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| T-cell lymphoma | D016399 | — | — | 2 | — | — | — | 7 | 9 |
| Pneumonia | D011014 | EFO_0003106 | — | 3 | — | — | — | 4 | 7 |
| Meningioma | D008579 | EFO_0003098 | D32.9 | 3 | — | — | — | 3 | 6 |
| Hematologic neoplasms | D019337 | — | — | 2 | — | — | — | 4 | 6 |
| T-cell lymphoma peripheral | D016411 | — | — | 1 | — | — | — | 5 | 6 |
| Wounds and injuries | D014947 | — | T14.8 | 1 | — | — | — | 4 | 5 |
| Mycoses | D009181 | — | B35-B49 | 2 | — | — | — | 2 | 4 |
| Pituitary neoplasms | D010911 | — | — | 2 | — | — | — | 2 | 4 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | 1 | — | — | — | 3 | 4 |
| Infarction | D007238 | EFO_0009463 | — | 1 | — | — | — | 3 | 4 |
Show 71 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 12 | 12 |
| Communicable diseases | D003141 | — | — | — | — | — | — | 9 | 9 |
| Covid-19 | D000086382 | — | — | — | — | — | — | 9 | 9 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | — | — | 7 | 7 |
| Sclerosis | D012598 | — | — | — | — | — | — | 7 | 7 |
| Neurodegenerative diseases | D019636 | EFO_0005772 | G31.9 | — | — | — | — | 7 | 7 |
| Myocarditis | D009205 | — | I51.4 | — | — | — | — | 6 | 6 |
| Depression | D003863 | — | F33.9 | — | — | — | — | 6 | 6 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 4 | 4 |
| Gastrointestinal diseases | D005767 | — | — | — | — | — | — | 4 | 4 |
Show 286 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Fludeoxyglucose f 18 |
| INN | fludeoxyglucose (18f) |
| Description | 2-deoxy-2-((18)F)fluoro-alpha-D-glucose is a 2-deoxy-2-((18)F)fluoro-D-glucopyranose and a 2-deoxy-2-fluoro-alpha-D-glucose. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 105851-17-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1092067 |
| ChEBI ID | 31617 |
| PubChem CID | 450503 |
| DrugBank | — |
| UNII ID | 0Z5B2CJX4D (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 62,059 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
134 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use